The Ritedose Corporation Inc., a CDMO specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, has partnered with Verona Pharma plc as the development and manufacturing partner of Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD).   The U.S. FDA approved Ohtuvayre on June 26 for the maintenance treatment of COPD in adult patients. It is the first inhaled product with a novel mechanism of action avai...